Isomorphic Labs raises $5bn in ‘one of UK tech’s biggest funding rounds’

GettyImages 2176921867 business meeting with diverse professionals discussing strategy in modern conference room with city...

London-based AI drug discovery firm Isomorphic Labs has raised $5bn (£3.8bn) in one of the largest funding rounds in British tech, as investors bet billions on AI transforming the pharmaceutical industry.

The Google Deepmind spinout, led by Nobel Prize-winning scientist Sir Demis Hassabis, announced the oversubscribed Series C round on Tuesday, co-led by US venture capital giants Greenoaks and Sequoia Capital.

Andreessen Horowitz also participated, alongside Alphabet, Thrive Capital, MGX, GV, Capital G, Temasek and the UK government’s Sovereign AI Fund.

The investment follows reports last month that Isomorphic was seeking a valuation of up to $50bn, compared with roughly $17.5bn previously. The company has not disclosed its valuation following the latest raise.

The $5bn injection comes just six months after Isomorphic secured $2.1bn in Series B funding, bringing its total disclosed external funding to approximately $7.7bn since 2025.

Stay in the know

Three daily briefings with the key market moves and top business and political stories.

SUBSCRIBE HERE

AI minister Kanishka Narayan welcomed the announcement, calling it “one of the biggest Series C rounds in UK tech history”.

“Their work could fundamentally change how new medicines are discovered and accelerate the development of life-changing treatments for patients around the world,” he said.

“I’m proud that the UK Government’s Sovereign AI Fund has made a follow-on investment in the company, backing its continued global growth.”

Billions raised but clinical trials still ahead

Founded in 2021, Isomorphic uses AI to design potential medicines by predicting how molecules interact with biological targets, aiming to reduce the time and cost of drug development.

Its proprietary drug design engine, ‘IsoDDE’, combines AI simulation models to identify and refine potential treatments across different diseases.

The company is developing its own medicines targeting cancer and immune disorders, alongside partnerships with pharmaceutical companies including Eli Lilly, Novartis and Johnson & Johnson.

However, despite raising billions, Isomorphic has yet to begin testing its own drug candidates in humans.

understands the company remains in late-stage preclinical development, with encouraging early results across its internal oncology and immunology programmes and partnered projects.

The latest funding will support the development of its AI models, expansion of its drug pipeline and construction of global bioengineering infrastructure as it prepares to enter clinical trials.

“Our drug design engine is generating molecules with unprecedented precision and speed,” said Hassabis.

“This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”

Original source Isomorphic Labs raises $5bn in ‘one of UK tech’s biggest funding rounds’

Back to home